Navigation Links
Hybrid Fuels, Inc. Announces FDA Approved Lab Selection for Azul Instant™ - "Be Ready in an Instant"
Date:2/2/2012

FORT LAUDERDALE, Fla., Feb. 2, 2012 /PRNewswire/ -- Hybrid Fuels, Inc., (Pink Sheets: HRID) announced today that after a lengthy and heavily scrutinized review process that it has selected a state-of-the-art FDA approved laboratory to manufacture all new orders of Azul Instant™.

The laboratory was chosen based on its compliance standards and ability to ramp capacity quickly due to the increasing demand for the Azul Instant™ product in the market.  The laboratory is a cGMP (current good manufacturing practice) compliant facility and meets all FDA requirements to manufacture food supplements and over the counter pharmaceuticals.  Azul Instant™ will be manufactured in the USA. 

Azul Instant™ was developed by the scientific research and development team of Nouveau Life Pharmaceuticals.  The formula was developed with the same principals as other erectile dysfunction pharmaceuticals but in a safe and natural formulation.  Patients will now receive the NATURAL benefits of Azul Instant™ without experiencing the side effects associated with prescription medications. While there are other natural alternative supplements on the market today, Azul Instant™ is the only male enhancement product that works within 5 minutes.  Azul Instant™ lasts for up to 48 hours and has proven to help enhance sexual stamina, endurance, strength and energy with no side effects.

Azul Instant™ is marketed under Nouveau Life Pharmaceuticals, Inc., the Company's pending name change.  For more information, go to www.azulnow.com

About Hybrid Fuels, Inc.

The company was incorporated in the state of Nevada in 1998 as Polo Equities.  It has primarily been a development stage company with management focused on developing innovative business opportunities and further advancing technologies. 

Forward-Looking Statements - This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that could cause future results to differ materially from the forward-looking statements. You should consider these factors in evaluating the statements herein, and not rely on such statements. The forward-looking statements in this release are made as of the date hereof and Hybrid Fuels, Inc. undertakes no obligation to update such statements.

CONTACT:
Hybrid Fuels, Inc. - 954-903-2993


'/>"/>
SOURCE Hybrid Fuels, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. University of Michigan Study Shows SEQUENOMs MassARRAY Technology Identifies HPV Infections Missed by Standard Hybridization Test
2. Philips and ACC Address the Growing Demand for Minimally Invasive Cardiology Interventions by Showcasing Hybrid OR Solutions at ACC 2010
3. Frost & Sullivan Award Highlights Hybridyne Technologies Outstanding Technology Innovation
4. Cardicas Automated Anastomosis Systems Featured at Advances In Robotic And Hybrid Coronary Revascularization Meeting
5. MetroSouth Surgeon Pioneers Hybrid Treatment of Large Hiatal Hernias and Reflux
6. Hybrid Fuels, Inc. Acquires Marketing Company Focused on Multi-Billion Dollar Nutraceutical/Pharmaceutical Industry
7. Hybrid Fuels, Inc. Announces New Business Strategy
8. Ventana Medical Systems, Inc. and Advanced Cell Diagnostics Enter Worldwide Co-Promotion Agreement for Fully Automated RNA In Situ Hybridization Assay Systems
9. Synteract Releases SynCapture Version 1.5 of Its Hybrid Electronic Data Capture (EDC) System
10. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
11. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... 2016  Compass Diversified Holdings (NYSE: CODI ... of leading middle market businesses, announced today its consolidated ... 2016. First Quarter 2016 Highlights , ... or "Cash Flow") of $13.6 million for the first ... $15.0 million for the first quarter of 2016; ...
(Date:5/4/2016)... May 4, 2016 Yissum ... announced today that it had signed an exclusive ... , developer of novel protein degradation and immunomodulatory drugs ... commercialization of drug candidates representing first-in-class therapy for hematologic ... not disclosed. The novel technology was developed ...
(Date:5/4/2016)... 4, 2016 Research ... "Global Acute Myeloid Leukemia Market and Competitive ... offering.       (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... Market and Competitive Landscape Highlights 2016, provides ... products, Acute Myeloid Leukemia epidemiology, Acute Myeloid ...
Breaking Medicine Technology:
(Date:5/5/2016)... ... May 05, 2016 , ... Dr. Benjamin Stong of Kalos Facial ... treatment. Dr. Stong is double board certified and the only facial plastic surgeon ... of hair loss. Non-surgical therapies such as stem cells can be used to provide ...
(Date:5/5/2016)... ... May 05, 2016 , ... In honor of National Nurses ... people all over the United States to thank a nurse who's made a difference ... donate $5 to the American Red Cross of San Diego/Imperial Counties (up to $10,000) ...
(Date:5/5/2016)... ... May 05, 2016 , ... Chronic stress can have a silent, ... can weaken the immune system and increase inflammation, both of which raise the risk ... adult congenital heart disease program at Harvard-affiliated Massachusetts General Hospital. Chronic stress also can ...
(Date:5/5/2016)... N.J. (PRWEB) , ... May 05, 2016 , ... ... patients with cancer, today announced a new collaboration with Imerman Angels to ... cancer anywhere in the world. , “Imerman Angels provides an emotional lifeline to patients ...
(Date:5/5/2016)... ... May 05, 2016 , ... Dermatologic surgeons performed nearly 10 million ... up 27 percent since 2012. , The results of the 2015 ASDS Survey on ... in skin cancer treatments and the growing popularity of soft-tissue fillers and body sculpting ...
Breaking Medicine News(10 mins):